Effects of Repeated Dose of Dorzagliatin on Insulin Secretion, Glucagon Release and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes

A total of 30 subjects will be recruited 15 with intermediate hyperglycemia and 15 in the tyep 2 diabetes group respectively. Eligible participants will undergo hyperglycemic-clamp/oral glucose tolerance at baseline and after 4 weeks of dorzagliatin treatment.

Start Date02 Apr 2025

Sponsor / Collaborator

The Chinese University of Hong Kong

ChiCTR2500095194

/ SuspendedNot ApplicableIIT

Research of the efficacy and safety of dorzagliatin on latent autoimmune diabetes in adults(LADA)

Start Date10 Jan 2025

Sponsor / Collaborator-

NCT06222476

/ Not yet recruitingNot ApplicableIIT

A Multicentric, Prospective, Randomized Study Evaluating the Improvement of Renal Function Outcomes With Dorzagliatin in Patients With Type 2 Diabetes Mellitus With Early Kidney Injury.

The main purpose of this study is to explore the improvement of renal function before and after the intervention of dorzagliatin in patients with type 2 diabetes.

Start Date20 Feb 2024

Sponsor / Collaborator

Nanjing Drum Tower Hospital

100 Clinical Results associated with Dorzagliatin

100 Translational Medicine associated with Dorzagliatin

100 Patents (Medical) associated with Dorzagliatin

Literatures (Medical) associated with Dorzagliatin

01 Jun 2025·Molecular Metabolism

Therapeutic management of PI3Kα inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3Kα inhibitor therapy

Article

Author: Li, Yongguo ; Ye, Wei ; Kang, Yu ; Li, Guiling ; Cheng, Xiaobo ; Chai, Ranran ; Liu, Shihuang ; Huang, Ai ; Wei, Wei ; Zheng, Kewei ; Jin, Guanqin ; Yi, Huan

OBJECTIVES:

The phosphatidylinositol 3-kinase (PI3K) signaling pathway is a pivotal target in cancer treatment, driving substantial investigation into PI3K inhibitors (PI3Ki). However, the common on-target adverse effect of hyperglycemia presents a substantial challenge to their clinical application. There is an urgent need to discover an anti-hyperglycemic agent that maintains the efficacy of PI3Ki.

METHODS:

We conducted a comprehensive study to explore the interaction between exogenous hyperinsulinemia and PI3Ki in SKOV3 and OVCAR3 ovarian cancer cell lines. We used Western blotting, CCK-8, and EdU assays to determine the effect of this interaction on cell proliferation. In addition, we evaluated the anti-hyperglycemic effects of dorzagliatin in a PI3Ki-induced hyperglycemic mice model. Cell line-derived xenograft (CDX) models were employed to evaluate the in vivo tumor growth inhibitory effects of combining dorzagliatin with PI3Ki.

RESULTS:

Western blot analysis demonstrated that insulin activated the AKT/INSR/mTOR pathway, reversing PI3Ki-induced p-AKT inhibition. Insulin also attenuated the anti-proliferative effects of PI3Ki. In the hyperglycemic mouse model, dorzagliatin significantly reduced blood glucose levels compared to controls. The combination therapy group (Dorzagliatin + PI3Ki) in CDX models showed a marked reduction in tumor volume. Dorzagliatin not only mitigated hyperglycemia but also enhanced the anti-tumor effects of PI3Ki. A clinical trial (NCT06117566) in cervical cancer patients supported these findings, showing that dorzagliatin stabilized blood glucose levels, facilitated body weight recovery, and achieved a confirmed partial response (PR).

CONCLUSIONS:

Dorzagliatin shows promise for managing PI3Ki-associated hyperglycemia, thereby enhancing its therapeutic efficacy. The activation of liver glycogen kinase and insulin regulation may be key mechanisms underlying its therapeutic benefits.

14 Apr 2025·Anti-inflammatory & anti-allergy agents in medicinal chemistry

Inclusive Drug Designing of Novel Indole Derivatives using Rationale, Pharmacophore Mapping and Molecular Docking

Article

Author: Mehra, Anuradha ; Sangwan, Rekha ; Mehra, Aryan ; Sharma, Rahul ; Mittal, Amit

Introductions/Background::

The presence of insufficient insulin signaling in type 2 diabetes arises due to either insulin resistance or impaired insulin secretion, ultimately lead-ing to elevated blood glucose levels, a condition known as hyperglycemia. Diabetes poses a pervasive worldwide challenge, with its prevalence steadily surging in both developed and developing nations. A promising avenue for improving the management of diabetes type 2 involves the exploration of glucokinase activators as an innovative therapeutic target. Nota-bly, a recent breakthrough in this area has been the market approval granted by the Japanese FDA for the use of the innovative GKA, Dorzagliatin, in the treatment of diabetes type 2.

Objective::

To augment the management of diabetes type 2 and mitigate the undesirable side effects linked to prolonged use of conventional medications, this research endeavor sought to create innovative glucokinase activators.

Methods::

The ZINC database yielded a collection of 56 compounds, each showcasing a 40% structural similarity to 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid. These compounds, all featuring the distinctive indole core, were meticulously selected for further investigation. Structural illustrations were crafted using ChemBioDraw Ultra, and 1.5.6 AutoDock Vina was for molecular docking. The Swiss ADME algorithm facilitated online log P predictions, while the software PKCSM was utilized to forecast the toxicity profiles of the leading com-pounds. DFT analysis was done to ensure the stability of compounds by using Gaussian 16 quantum chemistry software and Mulliken charge distributions used to optimize molecular geometries.

Results::

Among all the compounds, RS33 and RS37 exhibited the highest affinities for GK receptors, with the docking scores of -8.93 and -8.44 kcal/mol, respectively. These com-pounds follow Lipinski’s Rule, indicating promising absorption and excretion profiles through the gastrointestinal tract. Compared to standard drugs Dorzagliatin (GKA) and MRK (co-crystallized ligand), both RS33 and RS37 demonstrate no AMES toxicity, skin sensitiza-tion, and hepatotoxicity. RS43 is the most stable compound as it has high ΔE, η, and χ in DFT analysis.

Conclusion::

The novel-designed lead molecules demonstrate an enhanced pharmacokinetic profile, superior binding affinity, and minimal toxicity, based on computational study. These attributes make them promising candidates for further optimization as glucokinase activators.

01 Oct 2024·MICROBIAL PATHOGENESIS

Identification of small molecule glucokinase activators for the treatment of diabetes based on plants from the traditional Chinese medicine: In silico analysis

Article

Author: Moussamih, Samya ; Douiyeh, Imane ; Safi, Amal ; Kettani, Anass ; Regragui, Anas ; Khamlich, Jihane ; Saih, Asmae

Mutations in glucokinase (GCK) can either enhance or inhibit insulin secretion, leading to different forms of diabetes, including gestational diabetes. While many glucokinase activators (GKAs) have been explored as treatments, their long-term effectiveness has often been unsatisfactory. However, recent interest has surged with the introduction of dorzagliatin and TTP399. This study investigates the efficacy of four previously studied compounds (Swertiamarin, Apigenin, Mangiferin, and Tatanan A) in activating GCK using computational methods. Initial molecular docking revealed binding affinities ranging from -6.7 to -8.6 kcal/mol. The compounds were then evaluated for drug-likeness and pharmacokinetic properties. Re-docking studies were performed for validation. Based on their favorable binding affinities and compliance with Lipinski's rule and ADMET criteria, three compounds (Swertiamarin, Apigenin, and Tatanan A) were selected for molecular dynamics (MD) simulations. MD simulations demonstrated that Swertiamarin showed excellent stability, as indicated by analyses of RMSD, RMSF, radius of gyration (Rg), hydrogen bonding, and principal component analysis (PCA). These results suggest that Swertiamarin holds promise for further investigation in in vivo and clinical settings to evaluate its potential in enhancing GCK activity and treating diabetes. This study assessed the potential of four compounds as GCK activators using molecular docking, pharmacokinetic profiling, and MD simulations. Swertiamarin, in particular, showed significant stability and adherence to drug-likeness criteria, making it a promising candidate for further research in combating diabetes.

News (Medical) associated with Dorzagliatin

21 Nov 2024

·www.businesswire.com

Versant Ventures Unveils Pep2Tango Therapeutics Inc.

POTOMAC, Md.--( BUSINESS WIRE )--Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the significant, undisclosed round will support development of the company’s novel unimolecular tetra-receptor agonist peptides to treat obesity and related conditions. GLP-1-based therapies have proven efficacy in treating obesity and associated co-morbidities, but come with significant drawbacks. These include up to 40% of weight loss from muscle mass reduction, potentially leading to long-term side effects, especially in elderly patients. This limitation, in addition to tolerability issues, reduces the long-term utility of these agents. Pep2Tango’s lead drug candidates are engineered to overcome these drawbacks. They are unimolecular multi-receptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors. This unique combination of targets in one molecule is truly differentiated with key advantages compared with first-generation drugs on the market and therapies currently in development. Preclinical studies of Pep2Tango’s molecules have demonstrated superior weight loss versus tirzepatide, primarily through selective fat mass loss with preservation of muscle mass, improved blood lipid profiles, better glycemic control, and beneficial effects on the liver. The company’s programs were developed by a deeply experienced team led by President, CEO and Chairperson Cristina Rondinone, Ph.D., and CSO Soumitra Ghosh, Ph.D. Dr. Rondinone previously was president of Cellarity, and SVP and head of cardiovascular, renal and metabolic diseases at AstraZeneca plc. Prior to that, she held roles of increasing responsibility in cardio-metabolic disease research and development at MedImmune Inc., Roche and Abbott Laboratories, where she led the research and development of multiple molecules that moved to clinical trials including Rezdiffra ™ , dorzagliatin and bentracimab. Dr. Ghosh is a co-founder of multiple biotech companies and served as executive director for research at Amylin Pharmaceuticals Inc., where he was involved in development efforts culminating in the approvals of Byetta ® , Symlin ® , Bydureon ® and Myalept ® . Dr. Ghosh also served as president of the Peptide Therapeutics Foundation. “We are delighted that Versant is backing Pep2Tango as we advance our programs towards clinical development,” said Dr. Rondinone. “There is a critical need to develop safe and highly efficacious drug therapies for obesity that preserve muscle mass and Pep2Tango’s approach should positively impact the lives of patients.” “We are thrilled to partner with the seasoned team of experts at Pep2Tango,” said Carlo Rizzuto, Ph.D., managing director at Versant and a Pep2Tango board member. “We are convinced that the company’s tetra-receptor agonists have best-in-category potential with respect to magnitude and quality of weight loss, as well as improving metabolic and cardiovascular health, that could redefine obesity treatment.” Pep2Tango Therapeutics is focused on CMC development activities to scale up drug candidate manufacturing and on running IND-enabling studies for a rapid transition to first-in-human clinical studies. An IND submission is expected in 2025. About Pep2Tango Therapeutics Inc. Pep2Tango Therapeutics is a biotechnology company founded in 2021 by seasoned pharmaceutical executives with a long track record of successful drug development. The company’s vision is to develop next generation peptide drugs that target unmet medical needs, including for metabolic, endocrine, CNS and cardiovascular disorders. Pep2Tango’s novel drug development approach for obesity focuses on unimolecular peptides that target multiple receptors, allowing for superior weight loss efficacy, muscle mass preservation, improved tolerability, and streamlined development and manufacturability. The company is backed by Versant Ventures. About Versant Ventures Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 100 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com .

Drug ApprovalIPO

16 Feb 2023

·www.prnewswire.com

111, Inc. Hosts Hua Medicine Launches First Official Flagship Store

SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- On February 15, 2023, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced that during the HuaTangNing® Market Launch for Innovative Commerce Cooperation, Dr. Yu Gang, Co-founder and Executive Chairman of 111, and Dr. Chen Li, Founder and CEO of Hua Medicine (HKEx stock code: 2552.HK), jointly unveiled the plaque of Hua Medicine's first official online flagship store on 111. 111 is committed to digitally connecting patients with medicine and healthcare services, aspiring to build itself into an integrated online and offline healthcare platform. The official flagship store launched by Hua Medicine on 111 will serve as an official window to showcase the outstanding brand image of Hua Medicine and an important platform for Hua Medicine to better serve both patients and doctors. For its part, 111 will further help Hua Medicine expand its commercial layout, broaden its drug supply and distribution channels, and explore innovative and diversified supply service modes. The official flagship store will provide patients with Hua Medicine's innovative treatment concepts, carry out patient education on drug safety and other topics, and release the latest news from Hua Medicine. Dr. Yu Gang, Co-founder and Executive Chairman of 111, said: "Hua Medicine is a leader in innovative drug research and commercialization in China. Over the years, it has devoted itself to the research and development of original drugs. HuaTangNing®, a first-in-class drug of its kind, is from Hua Medicine. The official opening of its flagship store on 111 is a timely and innovative measure taken by a Chinese innovative pharmaceutical company to embrace the Internet. At the same time, it also marks a key milestone for 111 and Hua Medicine in the exploration of online cooperation. 111 will work with Hua Medicine to make cutting-edge innovative drugs more accessible for diabetes patients, empower diabetes treatment as well as patient management, and contribute value to society." Dr. Li Chen, Founder and CEO of Hua Medicine, said: "111 is a benchmark player in China's Internet medicine and healthcare industry, equipped with leading digital technology and smart supply chain. We are very much looking forward to Hua Medicine's cooperation with 111, as we provide innovative solutions of health management and medical services through the online flagship store. In the future, Hua Medicine will continue to explore partnership opportunities with Internet channels to benefit more diabetic patients." About Hua Medicine Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. As Hua Medicine's cornerstone product (dorzagliatin tablets), targeting the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients, it has been approved by the National Medical Products Administration (NMPA) of China in September 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. About 111, Inc. 111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring. For more information on 111, please visit: . Forward-Looking Statements This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. SOURCE 111, Inc.

27 Sep 2021

·www.biospace.com

Hua Medicine May be Sending Type 2 Diabetes into Remission

Is it a DREAM? On September 26, news emerged from Suzhou, China, that a glucokinase activator being developed by Chinese pharmaceutical company Hua Medicine may be heading toward making diabetes remission a reality. “DREAM” is a follow-up, observational clinical study of the Phase III SEED clinical study of dorzagliatin, a first-in-class glucokinase activator, which is being conducted in drug-naive Type 2 diabetes patients to determine its safety and efficacy. Its main objective is to determine if patients who participated in the SEED trial and achieved glycemic control as defined by investigators could maintain this for a minimum of 52 weeks without the intervention of any glucose-lowering medication. And many of them did. The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed. Professor Jianhua Ma, director of the department of endocrinology at Nanjing First Hospital, standing member of the Chinese Diabetes Society and one of the principal investigators on the study, presented the findings at the 6th China BioMed Innovation and Investment Conference. “Dorzagliatin, a new class of glucokinase activator, has demonstrated the ability to effectively improve early phase insulin secretion and beta cell function and insulin resistance resulting in Type 2 diabetes remission,” Ma said, adding that dorzagliatin monotherapy had previously demonstrated stable long-term efficacy and a good safety pro the SEED study. “The DREAM study again showed positive results, where patients who reached normal blood glucose level after dorzagliatin treatment were able to maintain their blood glucose level and beta cell function after discontinuation of medication.” Ma went on to say that the study is of “great significance in expanding the treatment options for type 2 diabetes.” Hua Medicine is a clinical-stage drug development company based out of Shanghai, China, focussing on novel therapies for the treatment of diabetes and CNS disorders. According to Hua Medicine CEO, founder, and chief scientific officer Dr. Li Chen, China has the world’s largest number of diabetes patients, with the number of type 2 patients exceeding 120 million. He added that prevention and control of diabetes have become a “strategic imperative” in addressing this major public health issue. “The positive results of the DREAM study have strengthened our confidence in the cure of Type 2 diabetes,” Chen said. “Hua Medicine will continue to explore the broad prospects of monotherapy and combination therapy based on dorzagliatin, while further conducting typing studies and using a combination of big data and artificial intelligence for the precise treatment of Type 2 diabetes.” Per the Centers for Disease Control and Prevention (CDC), more than 34 million Americans have diabetes (around 1 in 10), with approximately 90-95% of the cases being Type 2. This is not the first time the idea of diabetes remission has been proposed. In 2020, Dr. Ebaa Al Ozairi, chief medical officer at the Dasman Diabetes Institute in Kuwait said that Type 2 diabetes remission with weight loss is possible and most likely for younger patients who sustain more weight loss and have had the disease for a shorter period of time. “We can no longer talk and tell our patients that diabetes is a chronic disease,” Ozairi, who is also an American Board of Physician Nutrition specialist, said during a presentation at ObesityWeek Interactive. “We have to give them the hope that we know today that diabetes remission is not a myth and is actually a reality. We really need to rethink treatment of Type 2 diabetes, so if it is treated early, we can achieve remission.” In 2018, Danish diabetes leader Novo Nordisk announced that it was upping its focus on stem cell therapy which replaces the beta cells missing in Type 1 diabetes patients with the aim of freeing patients from their dependence on insulin. In February, the company gave an update on its cell therapy efforts, saying that it expected to investigational new drug (IND) application toward the end of 2022, but that the initial indication would be in Parkinson’s disease, not diabetes. In January, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved an IND for its own cell therapy for Type 1 diabetes. Featured Jobs on BioSpace

First in ClassCell Therapy

100 Deals associated with Dorzagliatin

External Link

KEGG	Wiki	ATC	Drug Bank
D11342	-	-	DB15123

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	China	Hua Medicine (Shanghai) Co., Ltd.	30 Sep 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 2	-	The Chinese University of Hong Kong	01 Aug 2022
Maturity-Onset Diabetes of the Young, Type 4	Phase 2	Hong Kong	The Chinese University of Hong Kong	30 Sep 2020
Diabetes Mellitus, Noninsulin-Dependent, 2	Phase 2	China	Hua Medicine Ltd.	01 Sep 2015
Renal Insufficiency	Phase 1	China	Hua Medicine (Shanghai) Co., Ltd.	25 Apr 2019
Hyperglycemia	Clinical	Hong Kong	The Chinese University of Hong Kong	02 Apr 2025
Diabetic Nephropathies	IND Application	China	Hua Medicine (Shanghai) Co., Ltd.	-
Alzheimer Disease	Preclinical	China	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Diabetes Mellitus, Type 1	Preclinical	China	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Nonalcoholic Steatohepatitis	Preclinical	China	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Metabolic Syndrome	Preclinical	China	Hua Medicine (Shanghai) Co., Ltd.	11 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


1887-LB (ADA2024)	Not Applicable	-	19	Dorzagliatin 50mg	mmwfgcwfya(hrdogpfnvd) = sgjwyzsbwu pozicvkohw (ypxxqpgfyv ) View more	Positive	14 Jun 2024
				Placebo	mmwfgcwfya(hrdogpfnvd) = nkgupohowk pozicvkohw (ypxxqpgfyv ) View more
ADA2022	Not Applicable	Mason-Type Diabetes	8	Dorzagliatin 75mg	dzmihijtyu(ewfuxmptoo) = kcggcntqnf ltaqvtdoed (yoziulbshq ) View more	-	01 Jun 2022
				Placebo	dzmihijtyu(ewfuxmptoo) = scdiewtxon ltaqvtdoed (yoziulbshq ) View more
DREAM (ADA2022)	Not Applicable	Diabetes Mellitus, Type 2	69	Dorzagliatin	snryhadkjw(ryfmfxkxou) = uahcmlkrcy aubivupdwk (msgbgniexc, 53.4 - 77.0)	-	01 Jun 2022
NCT03141073 (DAWN, Pubmed \| Nat Med) Manual	Phase 3	Diabetes Mellitus, Type 2	767	metformin+Dorzagliatin	siahuoduyt(scjeumwwgr) = lgmrdgwmrj axvsecndnt (qphxpcxvzr, -1.11 to -0.93)	Positive	12 May 2022
				metformin+Placebo	siahuoduyt(scjeumwwgr) = sqqyiixnll axvsecndnt (qphxpcxvzr, -0.45 to -0.26)
NCT03173391 (SEED, Pubmed) Manual	Phase 3	Diabetes Mellitus, Type 2	463	Dorzagliatin	ghbunvnuxy(adhvvrcckr) = zrbkatdfqt ziwyolysdi (jtxnfbibib, -1.19 to -0.95)	Positive	12 May 2022
				Placebo	ghbunvnuxy(adhvvrcckr) = vkxgappcpm ziwyolysdi (jtxnfbibib, -0.68 to -0.32)
NCT03173391 (SEED, ADA2021)	Not Applicable	Diabetes Mellitus, Type 2	463	Dorzagliatin 75 mg	jxjdidtfkd(onpnusqgwv) = adstupxixb bxayjzofqr (ysovlwslix ) View more	Positive	01 Jun 2021
				Placebo	xniisvakae(phdjukgbbv) = lqusgguaox usldudadso (wtucsyqslk )
NCT03141073 (DAWN, ADA2021)	Not Applicable	Diabetes Mellitus, Type 2 Add-on	767	Dorzagliatin	xmltxiwwtu(wndvgpfkmk) = abpwohbjum hihkqzjdss (wpgvqdajll )	Positive	01 Jun 2021
				Placebo	xmltxiwwtu(wndvgpfkmk) = ziqqetxulq hihkqzjdss (wpgvqdajll )
NCT03173391 (HMM0301 \| SEED, NEWS) Manual	Phase 3	Diabetes Mellitus, Type 2	463	Dorzagliatin	ejnqzvmlwl(ursdkevfai) = rbzcppqtii gjxpyelrpk (suyyyatgnt ) View more	Positive	18 Jun 2020
				Placebo	ejnqzvmlwl(ursdkevfai) = tufzyrkqut gjxpyelrpk (suyyyatgnt ) View more
ADA2020	Not Applicable	Diabetes Mellitus, Type 2	463	Dorzagliatin 75 mg	jcgfasncea(saksrihkuo) = heewtstheh vnqrynlowz (ergkhtvabl ) View more	Positive	01 Jun 2020
				Placebo	szpkvmiozf(ezolyubtze) = rxtaukceiu iphvetxybu (bgqwmearoh ) View more
NCT02561338 (CTgov)	Phase 2	Diabetes Mellitus, Noninsulin-Dependent, 2	258	HMS5552 (HMS5552 Dose 1)	tmbuwhgjnd(syfosakpcb) = lbbtefeorf tcdjkkrruw (wackvywekq, hnaqmhyagh - moqvxklzeo) View more	-	10 Mar 2020
				HMS5552 (HMS5552 Dose 2)	tmbuwhgjnd(syfosakpcb) = qapukqaezd tcdjkkrruw (wackvywekq, wycdximtqz - konuhcpudm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dorzagliatin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation